Document Detail

Magnetic Fe₃O₄ nanoparticles and chemotherapy agents interact synergistically to induce apoptosis in lymphoma cells.
MedLine Citation:
PMID:  21187919     Owner:  NLM     Status:  MEDLINE    
The purpose of this study was to investigate the potential effects of combination therapy using magnetic nanoparticles of Fe₃O₄ (MNP-Fe₃O₄) and chemotherapeutic drugs on lymphoma cells. Proliferation, inhibition, and viability of Raji cells were detected by MTT and trypan blue exclusion. The percentage of cells undergoing apoptosis was detected by flow cytometry using fluorescein isothiocyanate-annexin V and propidium iodide staining. p53 and nuclear factor-κB (NF-κB) protein levels were measured by Western blot. The results showed that proliferation of Raji cells was inhibited by adriamycin or daunorubicin in a dose-and time-dependent manner. Cell sensitivity was improved and the 50% inhibitory concentrations of adriamycin and daunorubicin decreased when combined with a MNP-Fe₃O₄ carrier. Interestingly, increased apoptosis in Raji lymphoma cells was accompanied by upregulation of p53 protein and downregulation of NF-κB protein. Furthermore, the combination of MNP-Fe₃O₄ with adriamycin or daunorubicin increased p53 protein levels and decreased NF-κB protein levels more than adriamycin or daunorubicin alone, indicating that MNP-Fe₃O₄ could enhance the effect of chemotherapeutic drugs on p53 and NF-κB. Similar results for cell apoptosis and protein expression were not observed for the groups treated with dexamethasone ± MNP-Fe₃O₄ (P > 0.05). These findings suggest a potential clinical application for MNP-Fe₃O₄ in combination with daunorubicin or adriamycin in the treatment of lymphoma.
Hongmei Jing; Jing Wang; Ping Yang; Xiaoyan Ke; Guohua Xia; Baoan Chen
Related Documents :
8223459 - Hybrid cell extinction and re-expression of oct-3 function correlates with differentiat...
6577429 - Identification of key regulated events early in the life of hybrid animal cells constru...
2409079 - Chloroquine impairs the interferon-induced antiviral state without affecting the 2',5'-...
10639329 - Targets of extinction: identification of genes whose expression is repressed as a conse...
8202449 - Cell-to-cell interactions suggesting a sexual process in herpetomonas megaseliae (kinet...
17192179 - Nectin-2-mediated entry of a syncytial strain of herpes simplex virus via ph-independen...
1396309 - Interleukin-1 is both morphogenic and cytotoxic to cultured rat ovarian cells: obligato...
20722049 - Induction of primordial germ cells from mouse induced pluripotent stem cells derived fr...
2258829 - Changes in the shape of leishmania major promastigotes in response to hexoses, proline,...
Publication Detail:
Type:  Journal Article     Date:  2010-11-19
Journal Detail:
Title:  International journal of nanomedicine     Volume:  5     ISSN:  1178-2013     ISO Abbreviation:  Int J Nanomedicine     Publication Date:  2010  
Date Detail:
Created Date:  2010-12-28     Completed Date:  2011-04-18     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  101263847     Medline TA:  Int J Nanomedicine     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  999-1004     Citation Subset:  IM    
Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Apoptosis / drug effects*
Blotting, Western
Burkitt Lymphoma / drug therapy*,  metabolism,  pathology
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Daunorubicin / pharmacology
Doxorubicin / pharmacology
Drug Synergism
Flow Cytometry
Magnetite Nanoparticles / chemistry*
NF-kappa B / metabolism
Tumor Suppressor Protein p53 / metabolism
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Magnetite Nanoparticles; 0/NF-kappa B; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 20830-81-3/Daunorubicin; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Non-invasive and transdermal measurement of blood uric acid level in human by electroporation and re...
Next Document:  Viral epidemics in a cell culture: novel high resolution data and their interpretation by a percolat...